Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan ...